Enlivex Ltd. (ENLV) Fair Value 2026

ENLV · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

3.0 /10

32 fundamental signals · 0 models active

Value Trap Risk

WARN (40/100)

Quick Summary — As of 2026-08-27, Enlivex Ltd. (ENLV) trades at $1.48. QOC: 3.0/10. Value Trap Risk: 40/100 (WARN). 0/13 models active.

Key Facts

Ticker
ENLV
Price
$1.48
Quality Score
3.0/10
Value Trap Risk
40/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Value Trap score of 40 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give ENLV?

0 Intrinsic Value Models vs. Current Price ($1.48)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Enlivex Ltd. (ENLV) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Enlivex Ltd. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About ENLV?

0 of 13 models are currently active for ENLV. See which stocks rank higher →

How Does ENLV Rank in Biotechnology?

Among 620 Biotechnology stocks, ENLV ranks #591 by Quality of Company score. CirclFi's QOC score of 3.0/10 evaluates 32 fundamental signals. A score of 3.0 signals below-average fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a biotech sector, Enlivex Ltd. operates in a sector where partnership revenue is a critical driver of valuation. Investors evaluating ENLV should weigh these sector-specific dynamics alongside our model-derived fair values.

Is ENLV a Value Trap?

CirclFi's Value Trap algorithm assigns ENLV a score of 40/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Enlivex Ltd.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Enlivex Ltd.'s fundamental quality profile registers 3.0/10. This concerning score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ENLV valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Enlivex Ltd. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

CLGNCollPlant Biotechnologies Ltd.QOC 3.1MENSJyong Biotech Ltd.QOC 3.0SPTXSeaport Therapeutics, Inc.QOC 3.1WINTWindtree Therapeutics, Inc.QOC 3.0CMNDClearmind Medicine Inc.QOC 3.1ARGXargenx SEQOC 2.9ATHEAlterity Therapeutics LimitedQOC 6.2ELOXEloxx Pharmaceuticals, Inc.QOC 5.1TILInstil Bio, Inc.QOC 4.5EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: CLGN · MENS · SPTX · WINT · CMND · ARGX · ATHE · ELOX · TIL · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to ENLV?

6 companies across all industries closest to ENLV’s Quality of Company score of 3.0/10.

DXSTDecent Holding Inc.QOC 3.0QMLSQumulusAI, Inc.QOC 3.0RDCMRADCOM Ltd.QOC 3.0UCLuCloudlink Group Inc.QOC 3.0CRNTCeragon Networks Ltd.QOC 3.0NVDANVIDIA CorporationQOC 10.0

Read investment analysis: DXST · QMLS · RDCM · UCL · CRNT · NVDA

Where Does ENLV Sit in CirclFi's Biotechnology Rankings?

ENLV is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Enlivex Ltd.’s Valuation?

What is Enlivex Ltd.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Enlivex Ltd. (ENLV). The Quality of Company score is 3.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ENLV overvalued or undervalued right now?

At $1.48, 0 of 0 active models suggest ENLV may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Enlivex Ltd.'s business model in Biotechnology.

What does a Quality of Company score of 3.0 mean for ENLV?

Enlivex Ltd.'s QOC of 3.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on ENLV?

CirclFi analyzes ENLV with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is ENLV a value trap in 2026?

Enlivex Ltd.'s Value Trap score is 40/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Enlivex Ltd. (ENLV) a Quality of Company score of 3.0/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/ENLV/ · Methodology
Primary sources for this ENLV valuation
  • Financial statements: Enlivex Ltd. 10-K and 10-Q filings on SEC EDGAR (CIK 0001596812) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ENLV as of ; valuations recomputed .